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Efficient and widespread gene transfer is required for 
successful treatment of Duchenne muscular dystrophy 
(DMD). Here, we performed the first clinical trial using 
a chimeric adeno-associated virus (AAV) capsid variant 
(designated AAV2.5) derived from a rational design strat-
egy. AAV2.5 was generated from the AAV2 capsid with 
five mutations from AAV1. The novel chimeric vector 
combines the improved muscle transduction capacity 
of AAV1 with reduced antigenic crossreactivity against 
both parental serotypes, while keeping the AAV2 recep-
tor binding. In a randomized double-blind placebo-
controlled phase I clinical study in DMD boys, AAV2.5 
vector was injected into the bicep muscle in one arm, 
with saline control in the contralateral arm. A subset of 
patients received AAV empty capsid instead of saline 
in an effort to distinguish an immune response to vec-
tor versus minidystrophin transgene. Recombinant AAV 
genomes were detected in all patients with up to 2.56 
vector copies per diploid genome. There was no cellular 
immune response to AAV2.5 capsid. This trial established 
that rationally designed AAV2.5 vector was safe and well 
tolerated, lays the foundation of customizing AAV  vectors 
that best suit the clinical objective (e.g., limb infusion 
gene delivery) and should usher in the next generation 
of viral delivery systems for human gene transfer.
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IntroductIon
Duchenne muscular dystrophy (DMD) is the most common 
severe, life-threatening form of muscular dystrophy in child-
hood. DMD is associated with progressive muscle degeneration, 
 weakness, and mortality. DMD is X-linked and is genetically 
inherited, caused by mutations in dystrophin, a large (427 kDa) 
cytoskeletal  protein that is normally expressed in skeletal and car-
diac muscle, as well as smooth muscle, brain, and retina in various 
isoforms.1 The  incidence of DMD is 1 in 3,500–5,000 newborn 
males.2 The gene encoding dystrophin is the largest identified to 
date,1 and the risk of spontaneous mutation is high (1/10,000 germ 
cells).
Because DMD is caused by recessive and monogenic muta-
tions in the dystrophin gene, this disease is thought to be amenable 
to correction or improvement by gene therapy. Gene replacement 
therapy for DMD is a promising strategy because in theory it 
could benefit all DMD patients regardless of the nature of their 
genetic mutations e.g., deletions and point mutations. A number 
of additional drugs are in development and include alternative 
gene therapy approaches, cell therapy, antisense oligonucleotides, 
and small molecule drug therapies.3 However, DMD presents with 
a multitude of challenges for the development of effective treat-
ments including the largest disease gene that requires miniaturi-
zation to be compatible with gene replacement vectors, the very 
large mass of target tissue that is widely distributed throughout 
the body with layers of biological barriers, and unknown changes 
at the cell membrane level that may impact on vector binding and 
uptake. Furthermore, the immunological components of DMD 
pathophysiology may also impact on the development and deliv-
ery of novel therapeutics and therefore assays of immune system 
recognition and response must be carefully integrated into clinical 
trial designs.
Recombinant adeno-associated virus (rAAV) vectors car-
rying a miniaturized functional dystrophin gene (designated 
minidystrophin) have the potential to arrest or reverse muscle 
 failure.4–6 Comprehensive proof of concept and preclinical  testing 
has evaluated the effectiveness of AAV-minidystrophin gene 
delivery in animal models of DMD including the mdx mice and 
dystrophin/utrophin double knockout mice. Minidystrophin 
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expressed after AAV delivery to dystrophin deficient models has 
been shown to: correctly localize to the sarcolemma, restore the 
missing  dystrophin-associated protein complex to the cell mem-
brane, ameliorate dystrophic pathology in mdx muscle, normalize 
myofiber morphology, normalize cell membrane integrity, restore 
missing dystrobrevin complex, partially restore α-syntrophin 
association with the cell membrane, partially restore nitric oxide 
synthase activity, reduce muscle fibrosis, reduce myofiber central 
nucleation, improve whole-body endurance and muscle force 
transduction, reduce kyphosis and limb deformation, and increase 
general health and lifespan.5–8
Genetic strategies that target the muscular dystrophies will 
ultimately require widespread delivery to a large volume of 
 skeletal musculature and/or cardiac tissue. Strategies to improve 
transgene expression to the musculature have included the use 
of AAV serotypes other than AAV2 and efforts to evolve tissue 
specificity variants by directed capsid evolution as well as mosaic 
vector with a mixture of capsid from different serotypes.9,10 It 
is clear that no single natural AAV serotype will be useful for 
every clinical application, nor will directed evolution evolve all 
characteristics  desirable for a clinical scenario simultaneously. 
Any given serotype may contain biological characteristics both 
beneficial and detrimental to the given clinical application. 
Instead of attempting to “fit” a known AAV serotype to a disease 
process or coevolve multiple traits in a single capsid, we chose 
to use a rational approach to identify capsid regions on alter-
native AAV serotypes responsible for enhanced skeletal muscle 
transduction and to combine these modifications into the AAV2 
capsid which offers the benefits of a well-defined safety profile 
coupled with purification ease. The availability of capsid protein 
sequences from several AAV serotypes, muscle transduction pro-
files with different serotypes of AAV vector and antigenic epitope 
information for AAV2, combined with the three-dimensional 
structure of the AAV2 capsid11 provided us valuable information 
to rationally design efficient vectors for clinical trials. Through 
mutagenesis with insertion and substitution, a chimeric AAV2-
AAV1 vector, dubbed AAV2.5, was designed to contain desir-
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Figure 1 Amino acid candidates responsible for efficient skeletal muscle transduction. (a) Capsid amino acids of low skeletal muscle transduc-
ing serotypes (AAV2, AAV3) versus high skeletal muscle transducers (AAV1, AAV6, AAV7, AAV8, AAV9) were aligned using the Vector NTI program 
(Invitrogen). Alignments were examined for distinct amino acids of AAV2 from the others. See text for additional modeling criteria. Amino acids 
boxed or marked with arrows were deemed to be of interest. AAV2.5 is composed of the five amino acids indicated by * and @. (b) Location of the 
five amino acids on a single VP subunit which were modified in the AAV2.5 variant. Notice that the five amino acids are located on opposite posi-
tions of one subunit. (c) Location of the same five amino acids (circles and arrows) in the context of an assembled AAV capsid pentamer. Notice that 
the five amino acids are now in close proximity when two subunits are assembled. The five amino acid changes are located near the twofold axis of 
symmetry. AAV, adeno-associated virus.
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to AAV2, AAV2.5 has similar transduction efficiency in several 
cell lines and binds to heparin sulfate in vitro. However, AAV2.5 
induces stronger transduction in skeletal  muscles than AAV2 and 
demonstrated lower crossreactivity to AAV2 neutralizing anti-
bodies (Nab).
The novel AAV2.5 capsid offering improved skeletal muscle 
gene transfer efficiency and potentially reduced immunogenicity 
compared with naturally occurring serotypes was next evaluated 
in a clinical trial for DMD utilizing the minidystrophin transgene 
cassette. The initial development of AAV2.5-minidystrophin 
clinical trial capitalized on the fact that AAV2 was the only sero-
type approved for clinical use, and AAV1 was the only other 
AAV serotype under serious consideration for clinical studies. 
To this end, a subset of amino acids (5aa) in AAV type 1 were 
constructed into type 2 capsid backbone. The engineering and 
testing of this  chimeric capsid in clinical setting has provided 
a paradigm where as the investigator is no longer obligated to 
natural viral isolates for gene delivery and can therefore address 
additional clinical concerns (e.g., capsid immune response) that 
lie outside of primary objective of measuring therapeutic trans-
gene expression.
Therefore the novel nature of the proposed therapeutic strategy 
and study population led to the inclusion of careful monitoring of 
both humoral and cell-mediated immune responses in this phase I 
clinical trial. We have recently reported elsewhere on unexpected 
findings related to dystrophin immunity observed in this trial.12 
A subset of patients were shown post-hoc to have had pre-existing 
immunity to dystrophin epitopes believed to be expressed by rever-
tant myofibers, and cellular immune responses to minidystrophin 
epitopes were also observed. We detail herein the immune response 
to the novel AAV2.5 capsid as well as other study endpoints, such 
as: (i) successful vector transgene delivery to all patients at each 
dose based on PCR analysis of biopsy sectioning, (ii) no difference 
in immune infiltration when comparing placebo to vector treated 
arms, (iii) lack of detectable immune response in empty vector only 
tissues, (iv) no CTL response to chimeric capsid at any dose. All 
and all, this trial established that rationally designed AAV capsid 
was safe, well tolerated and lays a foundation of customizing AAV 
vectors that ideally suit the clinical objective (e.g., heart tropic, liver 
detargeted, neuroselective, etc.).
results
rational design of AAV chimeric vectors
Several of the AAV serotypes characterized to date trans-
duce mouse skeletal muscle with greater efficiency than AAV2, 
e.g., AAV1, AAV7, AAV8, and AAV9.13–17 In an effort to identify 
candidate amino acids responsible for enhanced transduction of 
skeletal muscle the VP1 amino acid sequences of these serotypes 
with high muscular tropism were compared to AAV2 using an 
alignment (Figure 1a). The criteria for selection of amino acid 
candidates are: (i) they must differ from AAV2 and be similar to 
the high muscle tropism serotypes, (ii) they must be located in 
a structurally variable region (VR) on the capsid surface,18,19 or, 
(iii) they must be located in an AAV2 antigenic region that is rec-
ognized by an antibody. Shown boxed in Figure 1a are the amino 
acids which met all criteria with the exception of one amino acid 
depicted by @ (residue 716, AAV2 Vp1 numbering) due to its 
close proximity to four other amino acids.
Three variants were initially generated in which AAV2 was 
modified to resemble AAV1: AAV2.5, AAV2-Q325T/T329V, and 
AAV2-T450N/Q457N. In the AAV2.5 variant four residues were 
substituted with AAV1 amino acids (Q263A, N705A, V708A, 
T716N, AAV2 numbering) and one AAV1 amino acid (T265, 
AAV1 numbering) was inserted into the AAV2 capsid (amino 
acids indicated by the asterisks (*) and @ in Figure 1a and the 
3D model shown in Figure 1b,c). These mutations are all on the 
VRs of the virion surface (VR I and VR IX, Figure 1b). Based 
on the AAV atomic structure, AAV2.5 was designed because resi-
dues 263 and 265 intercommunicate with residues 706, 708 and 
717 (Figure 1c). The locations of all five amino acid mutations in 
AAV2.5 are close to the A20 antigenic epitope.18,20,21 The AAV2-
Q325T/T329V variant (AAV2 numbering; depicted by arrows on 
Figure 1a)) partially met the set criteria, the amino acids are con-
served in AAV8 but differ in AAV1, AAV7, and AAV9, and are not 
close to a mapped AAV2 antigenic site. The AAV2-T450N/Q457N 
(boxed only in Figure 1a) contains amino acids located in VR V.
The amino acid mutations in the three AAV2 variants did 
not influence the ability to generate recombinant AAV vectors 
compared to unmodified AAV1 and AAV2 capsids containing 
the same transgene cassette as judged by physical particle titers 
(Table 1). The AAV2.5 variant resembled AAV2 with respect to 
its ability to bind heparin in affinity columns used for purification 
(Table 1). Furthermore, the transduction profiles of these variants 
in cultured HeLa, Cos, and 293 cells were more like that of AAV2 
than AAV1 (Table 1).
Genetic modification of the AAV2 capsid can improve 
muscle transduction
To determine whether amino acids responsible for in vivo 
 transduction could be accurately predicted, the variants with a pack-
aged luciferase gene (AAV2.5-luciferase, AAV2-Q325T/T329V-
luciferase, and AAV2-T450N/Q457N) were evaluated for their 














AAV2 1.3–8.5 × 108 ++ ++ ++++ ++++ ++++ + +++
AAV1 1.3–15 × 108 − − + + + ++++ −
AAV2.5 5.0–9.2 × 108 ++ ++ ++++ ++++ ++++ +++ −
Q425T/T329V 6.9–13 × 108 N/D N/D ++++ N/D ++++ + N/D
T450N/Q457N 4.4–9.3 × 108 N/D N/D ++++ N/D ++++ ++ N/D
Abbreviations: AAV, adeno-associated virus; N/D, not done; vg, vector genome.
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ability to transduce skeletal muscle following injection of equiva-
lent genome-containing particles into the gastrocnemius muscle of 
BALB/c mice. Luciferase expression was evaluated over time using 
biophotonic in vivo imaging and compared to the parental AAV1 and 
AAV2 (for AAV2.5) or AAV2 (for AAV2-Q325T/T329V) viruses 
(Figure 2a and b, respectively). In skeletal muscle, the AAV2.5 vari-
ant consistently produced higher transgene expression than AAV2 
at all time points tested albeit not to the identical level as observed 
with AAV1 (Figure 2a). AAV1 exhibited 5–12.5-fold higher levels 
of light emission than AAV2; whereas AAV2.5 exhibited 1.8–5.5-
fold higher light emission than AAV2. Mice injected with AAV2.5 
exhibited high levels of expression up to 8.4 months postinjection. 
The expression level of the AAV2-Q325T/T329V variant was indis-
tinguishable from that of AAV2 (Table 1 and Figure 2b) and was not 
tested further. The third variant,  AAV2-T450N/Q457N exhibited a 
3.5-fold enhancement in transgene expression over AAV2 (Table 1), 
but only at a later time point postinjection (day 42 postinjection) 
and was not tested any further.
unique antigenic properties of the AAV2.5 capsid
The antigenic profile of the AAV2.5 vector was explored first by 
examining its recognition by the well characterized A20 anti-AAV2 
monoclonal antibody.21 These studies revealed that the ability of 
the A20 antibody to recognize the AAV2.5 vector is extinguished 
compared to its strong recognition of AAV2 (Table 1). Thus this 
data suggest that AAV2.5 may have an immune profile distinct 
from AAV2.
Minimal crossreactive neutralizing antibodies exist between 
AAV2 and other serotypes such as AAV122 (C. Li and RJ. Samulski, 
unpublished results). To determine whether the neutralizing 
antibody profile of AAV2.5 was more like AAV2 or AAV1, sera 
from mice treated with AAV1-luciferase, AAV2-luciferase, or 
AAV2.5-luciferase vectors were analyzed for neutralizing anti-
body crossreactivity. Shown in Figure 3a are the dilutions of the 
sera from AAV2, AAV2.5, and AAV1 injected mice needed for 
50% inhibition of infectivity of AAV2, AAV1, or AAV2.5 in 293 
cells. The sera from AAV2-treated mice neutralized infectivity of 
AAV2 more efficiently than the infectivity of AAV2.5 by fivefold. 
A similar finding was observed in the examination of the ability 
of AAV1 sera to inhibit the infectivity of AAV1 and AAV2.5. The 
converse was found to be true for sera from AAV2.5 injected 
animals which was observed to be four- and eightfold more 
efficient at neutralizing AAV2.5 compared to AAV2 or AAV1, 
respectively. Therefore AAV2.5 with minimal change of 5 aa has 
antigenic properties that are distinct from those of the paren-
tal viruses suggesting that the engineered AAV2.5 capsid may 
eliminate the AAV2 or AAV1 antibody recognized epitopes or 
change virion three-dimension structure and such that it is less 





























Figure 2 evaluation of skeletal muscle transduction of AAV2 mutants. 
(a) Skeletal muscle transduction of AAV1, AAV2, and AAV2.5 examined 
over time (days 3, 7, 21, 28, 42) using in vivo biophotonic imaging. 
The relative light units per region of interest in each injected mouse (n = 
6) are graphed over time. (b) Graphical representation of quantity of 
emitted light from transduction of AAV2 and AAV2-Q325T/T329V. The 
relative light units per region of interest in each injected mouse leg (n = 
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Figure 3 neutralizing antibody analysis to AAV2.5. (a) Crossreactive 
Nab between AAV1, AAV2, and AAV2.5. C57 mice were immunized with 
1 × 1010 particles of AAV/luc vectors via muscular injection. Thirty days 
later, sera from three mice was collected for Nab analysis. (b) The effect 
of AAV2 Nab on AAV2.5-induced transgene expression in vivo. Mice were 
immunized with AAV2/AAT viruses (left three panels) or not immunized 
(right panel), 2 months later, AAV2.5/luciferase (mouse right leg) and 
AAV2/luciferase (left leg) vectors with different dosages were applied in 
the same mice intramuscularly (5 × 109 particles, 1 × 1010 particles, or 
5 × 1010 particles), imaging was taken 6 weeks later post-luciferase vector 
injection. (c) Neutralizing antibody assay for human sera. The sera from 
36 human subjects were detected for Nab against AAV2 and AAV2.5. 
AAV, adeno-associated virus.
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likely to be neutralized by the sera of animals pretreated with 
AAV2 and AAV1.
Genetic modification of the AAV2 capsid enables 
repeat administration of variant vectors
The serological data described above suggested that AAV2.5 was 
antigenically distinct from the parental viruses. To test whether 
this phenotype would make this variant refractory to pre-exist-
ing antibodies and allow readministration in subjects previously 
treated with AAV2 vectors, in vivo studies were performed in 
which mice previously injected with an AAV2-AAT vector were 
subsequently injected intramuscularly (i.m.) with increasing 
doses of either AAV2-luciferase or AAV2.5-luciferase vectors. 
For direct comparison, each mouse received the same dose of the 
two vectors in separate leg muscles. In vivo biophotonic imag-
ing performed at 6 weeks postinjection of the luciferase express-
ing virus revealed no detectable expression from either vector 
at low doses (5 × 109 particles, Figure 3b). However, at higher 
doses (1 × 1010 particles (Figure 3b) and 5 × 1010 particles per 
leg (Figure 3b)) the AAV2.5-luciferase administered legs con-
sistently exhibited elevated transgene expression (~10–20-fold) 
over its AAV2-luciferase injected counterpart (Figure 3b). The 
enhanced transduction by AAV2.5 is interpreted as being due 
to both its inherently higher skeletal muscle transduction com-
pared to AAV2, as evidenced by its ~2–5.5-fold higher transgene 
expression over AAV2 observed in control mice with no previous 
exposure to AAV2 (Figures 2 and 3b, right panel) as well as to its 
ability to overcome pre-existing anti-AAV2 neutralizing antibod-
ies. However, although it is clear that the high dose of AAV2.5 
vector could escape AAV2 neutralizing antibody partially in vivo, 
we could not rule out the possibility that AAV2 neutralizing anti-
bodies completely block AAV2.5 transduction after  muscular 
injection in AAV2 pretreated mice when a much lower dose of 
AAV2.5 was used.
summary of late preclinical studies
Sera from 36 individuals were screened for neutralizing antibodies 
and pre-existing neutralizing antibody titers of >1:2 to AAV2 were 
seen in 75% of individuals while titers of >1:2 to AAV2.5 were 
seen in only 56% of individuals (Figure 3c). Of those individu-
als that have AAV2 Nab, a very high Nab antibody titer (≥100) is 
found in 25% of these individuals; whereas, only 19.5 % of indi-
viduals with Nab to AAV2.5 exhibit high Nab titer. Generally the 
titer against AAV2.5 is 2–20-fold lower than that against AAV2 in 
the Nab positive population. The data from this human sera neu-
tralizing antibody assay again support the conclusion that AAV2 
and AAV2.5 have different immune profiles.
A penultimate preclinical study was conducted to assess possi-
ble adverse interactions between the commonly prescribed corti-
costeroid prednisone and AAV-minidystrophin in C57/BL10 mice. 
No discernable adverse interaction and influences on transgene 
expression were observed (data not shown, see Supplementary 
Materials and Methods—Preclinical AAV2.5-Minidystrophin 
Studies).
The AAV-minidystrophin expression cassette including 
the cytomegalovirus (CMV) promoter and the polyadenyla-
tion signal site in the vector plasmid was fully sequenced on 
both strands except the inverted terminal repeats, which were 
difficult to sequence. A pivotal good-laboratory-practice toxic-
ity and biodistribution study evaluated AAV-minidystrophin 
delivery in C57/BL10 mice with timepoints up to 36 weeks post 
vector administration and doses up to 1 × 1012 vector genomes/
kg, which was equivalent to 10 times the highest dose proposed 
in the clinical trial. Overall, the AAV-minidystrophin vector 
caused no significant toxicity in C57BL mice, with all animals 
surviving until scheduled sacrifice. Effects on clinical chemistry 
parameters in the toxicity study were within the normal refer-
ence ranges, and there were no differential effects observed by 
histopathological analyses. There were no related effects on clini-
cal hematology parameters or gross necropsy observations. PCR 
biodistribution evaluations indicated that the vector remained 
concentrated in the injected muscle (data not shown, see 
Supplementary Materials and Methods—Preclinical AAV2.5-
Minidystrophin Studies).
regulatory approval process
The clinical protocol and Appendix M documents were reviewed 
by the Recombinant DNA Advisory Committee under the aus-
pices of the Office of Biotechnology Activities at the National 
Institutes of Health (NIH). The Nationwide Children’s Hospital 
institutional review board approved the study protocol. A 
 Pre-IND discussion was held with FDA before initiation of the 
pivotal toxicology and biodistribution study, and upon conclu-
sion of preclinical studies the IND was submitted to CBER/FDA 
(BB-IND 12936). The trial is registered with ClinicalTrials.gov 
(Reference no. NCT00428935).
clinical study design
The experimental design was a randomized double-blind placebo-
controlled study where vector was administered into one bicep 
and saline control in the contralateral arm. In a subset of patients, 
we substituted AAV empty capsid for saline in an effort to distin-
guish an immune response to vector versus minidystrophin trans-
gene. The active phase of the study included a 2-week baseline 
screening period, a 2-day inpatient period for vector injection and 
acute toxicity monitoring, and a 2-year outpatient follow-up and 
toxicity-monitoring period. Ongoing long-term follow-up will 
continue out to 15 years post vector injection. (Supplementary 
Figure S1). Blood and urine analyses were conducted in conjunc-
tion with outpatient clinics on post administration days 8, 15, 30, 
43, 53, 60, 90, and 120 and months 6, 9, 12, 18, and 24.
The study enrolled six DMD boys ranging in age from 5 
to 11 years and ranging in mass from 16 to 57 kg, each with 
unique and defined dystrophin mutations. Four boys had been 
on  corticosteroid medication schedules before vector injection 
(Table 2). All six patients were administered methylprednisolone 
(2 mg/kg, limited to <1 g total) four hours prior to vector admin-
istration, with repeat doses on the following two mornings. A 
MyoJect hypodermic needle (Oxford Instruments, Hawthorne, 
NY) was used to deliver 1.2 ml of vector in three equivalent boluses 
spaced 0.5 cm apart along an injection tract that was placed in a 
longitudinal trajectory relative to the biceps muscle orientation. 
Administration of AAV2.5-Minidystrophin to each subject was 
staggered to allow for at least 6 weeks of follow-up before the 
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next subject receiving the vector. There were two-dose cohorts of 
three subjects each that received unilateral i.m. delivery of either 
6 × 1011 vector genomes or 3 × 1012 vector genomes. Dosing was 
defined by locally administered dose as the vector was mediat-
ing production of a structural protein and not a secreted protein, 
and vector genomes remained localized to the region of the injec-
tion site. Internalized AAV capsid peptide competition for MHC 
presentation would also be more heavily influenced by the local-
ized dosing. As a result of the inclusion of an empty capsid control 
vector administered to the last two subjects, there was a full log 
difference in the capsid dose between subjects 1–3 and 5 and 6. 
Biopsies were taken at 1.5 month in the majority of patients and 
out to 3 months in two patients (Table 2).
clinical observations
Physical examinations were unremarkable with no symptoms of 
fever, lymphadenopathy, organomegaly, and no signs of inflam-
mation at the injection site. During the 2-year-long active phase 
of the trial monitoring, no serious or mild adverse events have 
been observed in any subject. A few minor adverse events were 
observed including sore throats, rashes and nausea, but they were 
not considered related to the vector administration as they are 
commonly seen in this age group of subjects (detailed in ref. 12). 
Hematology and chemistry panels that included an assessment of 
liver function also indicated that the gene vector was well toler-
ated in all subjects (Supplementary Figure S2). There were no 
abnormal elevations in the levels of creatine kinase, alkaline phos-
phatase levels, or lymphocyte counts in all blood samples tested.
AAV2.5-mediated gene delivery in patients
Biopsies were undertaken in four subjects (subjects 1, 3, 4, and 6) at 
d43 post administration, and in two subjects (subjects 2 and 5) at 
d90 post administration. The biopsy procedure utilized ultrasound 
imaging to guide the retrieval of the injected tissue. A battery of 
assays were undertaken on the biopsied muscle tissue and included: 
PCR analysis of vector genomes, immunolabeling of minidystro-
phin, tissue histochemistry including CD8 T-cell infiltration.
Quantitative Pcr of the vector genome in human 
muscle biopsies
The presence of the vector genomes was assessed in muscle biop-
sies from the left and right arms 1.5 and 3 months after injection. 
The transgene DNA was detected in 6 out of 6 patients, in only one 
arm with no detectable spread to the contralateral arm. The high-
est vector genome copy number per nucleus (diploid cell genome) 
detected in each patient is shown in Table 2.
detection of minidystrophin protein in muscle tissue 
biopsy
Cryothin-sections of the muscle biopsies were immunofluorescently 
stained with antibodies recognizing the dystrophin N-terminal 
region (present in both minidystrophin and endogenous revertant 
myofibers) or the C-terminal region (absent in minidystrophin but 
present in revertant myofibers). Limited minidystrophin expression 
was observed with appropriate localization to the sarcolemma in 
two of six subjects. In patients 3 and 6, only a few minidystrophin 
positive myofibers were detected by anti-N-terminus antibody but 
stained negative by anti-C-terminus antibody. However, in patients 
1, 2, 4 and 5, no minidystrophin positive myofibers were detected, 
suggesting that transgene expression was either very poor or extin-
guished in those patients (detailed in ref. 12).
Immunological studies
Post administration hematological testing indicated no abnormal 
changes in white blood cell counts, and there were no changes in 
markers of liver toxicity (Supplementary Figure S2). However, clin-
ical AAV2 administration has previously been associated immune 
recognition of AAV capsid peptides,23 and therefore we evaluated 
cellular and humoral immunological recognition of AAV2.5.
cell-mediated immunity to AAV2.5
Peripheral blood mononuclear cells (PBMCs) of the subjects were 
tested for recognition of potential AAV capsid and minidystrophin 
peptide epitopes by Elispot assay.23 Antigens used to stimulate these 
responses were pools of overlapping peptides spanning the AAV 




















1 8 45 22.6 Y <1:2 6.0 × 1011 Saline Low D43 0.75 ND 30–125
6.6 × 1011
2 9 50 28.5 Y 1:800 6.0 × 1011 Saline Low D90 0.01 ND 0–9
6.6 × 1011
3 9 46–50 35.5 N <1:2 6.0 × 1011 Saline Low D43 0.61 weak 0–9
6.6 × 1011
4 5 49–54 15.8 N <1:2 3.0 × 1012 Saline Intermediate D43 2.56 ND 0–11
3.3 × 1012
5 11 3–17 57.1 Y 1:100 3.0 × 1012 Empty capsid High D90 0.08 ND ND
6.6 × 1012
6 9 46–52 28.7 Y 1:2 3.0 × 1012 Empty capsid High D43 1.42 weak 1–25
6.6 × 1012
Abbreviations: AAV, adeno-associated virus; ND, none detected; qPCR, quantitative PCR.
aAAV2.5 minidystrophin vector genome dose (vector genomes/patient). bTotal capsid dose (minidystrophin + empty capsid in subject’s 5 and 6) capsid particles/
patient. cVector genome copy number isolated per nucleus as determined by qPCR (skeletal muscle cells are multinucleated).
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capsid VP1 protein. Peptides were 20 amino acids in length over-
lapping by 10 residues and thus would cover all epitopes of VP3 and 
stimulate CD4+ helper and CD8+ cytotoxic T cells. PBMCs from 
the subjects were cultured with the AAV capsid peptide pools for 
48 hours and then developed for interferon (IFN)-γ spot forma-
tion. Subject 1 showed AAV2.5 specific responses that substantially 
exceeded the threshold of 50 spot-forming cells (SFC) per million 
PBMC collected at two timepoints, d30 and d90, but not at other 
timepoints including d43, d53, and d60 post vector injection. In 
further analyses, the d30 time-point was confirmed as positive after 
stimulation with peptide pools spanning the capsid protein. Cell 
lines generated from this sample could not be expanded to support 
additional characterization. We did not observe significant T cell 
responses to AAV2.5 capsid antigens seen at any time-point before 
or after vector administration in any other subjects (Figure 4), how-
ever, some samples from subjects 2, 3, and 4 were weakly positive at 
various time points (sporadically >50 SFC/106 PBMC).
lack of cd8 infiltration into injected muscle
Cellular infiltrates were quantified in a blinded examination 
of bicep muscle biopsies. Evaluation of muscle biopsy sections 
immunofluorescent stained with anti-CD8 antibody showed 
no statistic difference in the counts of CD8+ cells between 
 AAV-minidystrophin injected and placebo (saline and empty 
capsids) injected biopsies (52.1 ± 35.2 and 41.9 ± 23.2 cells/mm3 
cross-section area, respectively). These cell counts were within the 
range commonly observed in patients with DMD.
Humoral immunity to AAV2.5
The AAV capsid itself is a completely foreign protein and there-
fore a humoral immune response to vector administration was 
anticipated. Pre-existing humoral immunity to AAV was not an 
exclusion criterion in this study with the rationale that the rel-
evance of in vitro assays of vector neutralization before i.m. 
administration is unknown due to a lack of previous clinical data. 
In order to characterize the humoral response to AAV2.5, titers 
of AAV neutralizing antibodies in serum were also evaluated in 
an assay involving in vitro transduction in the presence of sera 
from patients. Subject’s sera were screened for neutralizing anti-
bodies to both seroprevalent wild-type AAV2 and the synthetic 
AAV2.5 capsids. As detailed in Table 2, subjects 2 and 5 were 
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Figure 4 temporal t cell response to AAV2.5 capsid. Two capsid peptide pools were comprised of peptides spanning the AAV2.5 capsid sequence. 
Elispot assays measured interferon (IFN)-γ release upon peptide exposure, with the threshold for peripheral blood mononuclear cell (PBMC) recogni-
tion of an epitope within the peptide pool being 50 spots/106 PBMCs. Temporal responses are shown for subjects 001–006 in separate panels for the 
two peptide pools. AAV, adeno-associated virus.
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titers to both AAV2 and 2.5, with baseline titers of 1:800 and 1:100 
to both vectors, respectively (titers are the inverse of the highest 
serum dilution mediating 50% neutralization to either capsids). 
Baseline titers were <1:2 for both AAV2 and AAV2.5 for subjects 
1, 3, and 4, and Subject 6 had a baseline titer of 1:4 for AAV2 
and 1:2 for AAV2.5. Classical humoral responses were observed 
after AAV2.5-minidystrophin administration, with increases in 
Nabs that peaked from weeks 2 to 6 and ranged from 50× to 
1,000× baseline titers (Figure 5). Subject 2 who had high base-
line titers was the only subject who did not exhibit a classical post 
administration strong increase in neutralizing antibody titers, 
with titers at all time points staying within the range of 1:800 to 
1:2,000, approximately a 2.5× increase.
dIscussIon
Our study represents the first clinical trial of a synthetic rationally 
designed AAV vector, AAV2.5, and provides a preliminary insight 
to the clinical tolerability of this first-in-class gene vector. In this 
study, we have utilized the atomic structure of the AAV2 virion 
and homologous models generated for muscle tropism serotypes 
and VP1 sequence alignments as a guide to rationally design an 
AAV2 variant (AAV2.5) with altered transduction and antigenic 
profile from AAV2. We have successfully identified amino acids 
that differ between AAV2 and muscle tropism serotypes and 
located in a structurally VR. Most strikingly, the genetically modi-
fied AAV2.5 vector demonstrated the enhanced muscle  tropism 
and different antigenic properties from parents (AAV2 and 
AAV1). Furthermore, this study showed that i.m. administration 
of a laboratory-derived novel AAV2.5 gene  vector encoding 
minidystrophin at capsid doses up to 6.6 × 1012/kg capsid particles 
was well tolerated by all subjects, with no vector related adverse 
events observed.
AAV rational design
The Q263A substitution and T265 insertion in AAV2.5 are located 
in one of the most VRs in the common VP3 capsid protein (struc-
turally and at the amino acid sequence level) when AAVs are com-
pared. They are located in VR I. A structural comparison of the 
loop containing these amino acids on the capsid surface of the 
atomic structures of AAV1 and AAV2 shows a conformational 
difference in the main chain (Figure 6). This surface loop region 
is also predicted to be different in the homologous model gen-
erated for AAV2.5 from the atomic coordinates of AAV1 (data 
not shown) and AAV211 (Figure 6). This is one of the three most 
structurally divergent surface loops in main chain conformation 
when the structure of AAV8, another muscle tropism serotype, 
was compared to that of AAV2.24 The Q263A substitution and 
T265 insertion were also among the nine residues identified as 
contributing to AAV1 skeletal muscle transduction by the AAV1/
AAV2 domain swap study by Hauck et al.25 Like the AAV2.5 vec-
tor, their AAV-221-IV vector approached but did not quite reach 
the transduction profile of AAV1, strongly suggesting other capsid 
motif may be required.
Gene expression and immunological recognition
AAV2.5-mediated minidystrophin delivery to skeletal muscle was 
confirmed by vector DNA quantitative PCR (qPCR). Retrieved 
genome copy numbers (up to 2.56 copies/diploid genome in sub-
ject 4) were within the range of that observed in previous trials of 
i.m. administration of AAV vectors (Supplementary Table S1). 
However, the overall minidystrophin transgene expression 
detected in this clinical trial was low. Limited minidystrophin 
positive myofibers were detected in patients 3 and 6, but not 
in other patients. However, patients 2 and 5 had elevated T 
cell Elispot responses to dystrophin epitopes from endogenous 
revertants and/or transgene product after vector delivery, sug-
gesting a transient transgene expression.12 As an alternative to 
the hypothesis that minidystrophin-stimulated transient rec-
ognition by T cell PBMCs resulted in loss of expression before 
biopsy, the low levels of transgene expression could be partially 
explained by numerous factors, e.g., pre-existing anti-AAV neu-
tralizing antibodies (seen in patients 2 and 5), pre-existing T 
cell responses to endogenous revertant dystrophin epitopes that 
are also present on minidystrophin (seen in patients 2 and 4),12 
silencing of the CMV promoter in human dystrophic muscles, 
disease-associated inflammation, and low tropism of AAV2.5 to 
human muscle tissue.
With respect to these possibilities, we observed significantly 
higher vector genome copy numbers in muscle from patients who 
both lacked pre-existing Nab and who were also biopsied at ear-
lier time-point. Subjects 4 and 6, who received the high vector 
dose, also had the highest vector genome copy numbers detected 
(2.56 and 1.42 vg/dg, respectively), consistent with animal stud-
ies. Although subjects 4 and 6 retained the highest genome copy 







−5 0 5 10
Timepoint relative to AAV2.5 administration (weeks)



















Subject 5 Subject 6
Subject 2 Subject 3 (Low-capsid dose group)
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Figure 5 temporal neutralizing antibody response to AAV2.5. 
The temporal profile of the highest dilution of serum that neutralizes 
AAV2.5 transduction in vitro is shown for all six subjects. Subjects 1–3 
received the same dose of AAV2.5 capsid, 6.6 × 1011 capsid particles. 
Subject 4 received 3.3 × 1012 capsid particles. Subjects 5 and 6 received 
6.6 × 1012 capsid particles due to administration of empty capsid pla-
cebo (see table 2). AAV, adeno-associated virus.
Molecular Therapy  vol. 20 no. 2 feb. 2012 451
© The American Society of Gene & Cell Therapy
Clinical Evaluation of Custom-designed AAV Capsid in DMD Patients
of minidystrophin expression (subject 6), a strong indication of 
CMV promoter silencing in the injected muscle. Lower levels of 
vector DNA were detected in subjects 1 and 3 (0.75 and 0.61 vg/dg, 
respectively), but only subject was found to have minidystrophin 
positive myofibers. Subjects 2 and 5 had high levels of pre-existing 
neutralizing antibodies (1:800 and 1:100) to AAV2.5. They also 
had elevated T cells recognizing dystrophin. The humoral and 
T-cell immunity could have jointly contributed to the very low 
vector genome copy numbers (0.01 and 0.08 vg/dg, respectively) 
and the lack of detectable minidystrophin expression, again as 
predicted from animal studies (see Figure 3). Unfortunately 
due to the small size of this safety study, the variability in sub-
ject  characteristics and the two biopsy timepoints, it is premature 
to draw definitive conclusions regarding the association between 
pre-existing immunities and gene transfer and expression effi-
ciency, but mark a key observation that has been noted by more 
recent AAV studies (>50 exclusion of patients with pre-existing 
Nab in AAV1 CUPID trial).
With the caveat that many experimental differences exist 
between trials, it remains interesting to compare the current 
results with previous clinical studies. While minidystrophin 
expression was observed only at low levels in one subject from 
each dose cohort, there are similarities with clinical observations 
in other trials using similar doses of AAV via i.m. injections in 
the  AAV2-FIX, AAV2-AAT, and AAV1-AAT skeletal muscle 
clinical trials (Supplementary Table S2). In this present study, we 
observed T cell recognition of nonself-epitopes encoded by the 
minidystrophin in subject 5.12 Unpredicted T cell responses against 
self-epitopes encoded by the minidystrophin and the endogenous 
revertant dystrophin were also observed in subjects 2 and 4, appar-
ently as a result of priming by rare revertant myofibers. In contrast 
to this and previous studies, in the recently reported LGMD 2D 
trial with AAV1 α-sarcoglycan,26,27 no T-cell immunity against 
either the endogenous or the transgene-encoded α-sarcoglycan 
was detected. In fact, 5 out of 6 patients had efficient and long-term 
transgene expression. The starkly different outcomes between the 
DMD and LGMD 2D clinical trials could be attributed to differ-
ent complexity and underlying pathology of the diseases, choos-
ing of patients (deletion versus point mutations) and the use of 
different AAV serotype vectors (AAV2.5 versus AAV1), promot-
ers  (nonspecific CMV versus muscle-specific tMCK) and the 
transgenes (minidystrophin versus α-sarcoglycan). The ongoing 
oligo exon skipping studies for DMD should provide supportive 
evidence for “revertant myofiber” hypothesis or simply note that 
peripheral T-cell recognition is not indicative of  cytotoxic T-cell 
response.
In the present study, cell-mediated responses to the AAV 
capsid peptides were absent at baseline in all subjects. This 
absence of T cell response to AAV capsid epitopes in subjects 2 
and 5 who had high levels of pre-existing AAV Nab was somewhat 
unexpected. Interestingly, we did not observe any T cell response 
to AAV capsid in subjects 5 and 6 who received a 1 log higher 
AAV2.5 capsid dose than Cohort 1 due to the fivefold dose escala-
tion and the additional equal dose of empty capsid vector in the 
contralateral arm. In a minority of subjects, Elispot IFN-γ release 
approached and sometimes exceeded the threshold values con-
sidered positive, but there was no consistent pattern or  obvious 
relationship to the timing of vector administration.
significance of immunological data
This trial was the first to use a laboratory-derived novel AAV 
capsid to mediate gene delivery. The vector was well tolerated 
and there were no vector-related adverse events. These data are 
similar to a meta-analysis of all adverse events reported in 12 
AAV trials enrolling >400 subjects overall, in which no AAV vec-
tor related adverse event pattern was observed. The safety pro-
file observed in this trial supports further clinical evaluation of 
the  AAV-minidystrophin. However, T cell-mediated immune 
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Figure 6 topology of AAV2.5 virion. Surface topology view of the five VP monomers (in different colors) immediately surrounding the reference 
monomer in light blue. The symmetry operation that brings the monomer into contact is given in the labels. The positions of the AAV2.5 residue 
mutations are colored as in Figure 1b,c. (b) Top panel is a close up of the boxed region in the a. The bottom panel shows the same image rotated 
by ~75° and shows that the region containing the 263/265 amino acids are raised on the capsid surface. (c) Image showing a surface view (same as 
in Figure 1) of the loop containing the 263/265 region, VR III and VR IX (close to the 706, 709, 717 mutations) for AAV1 (purple), AAV2 (blue), and 
AAV2.5 (light blue). The positions of the AAV2.5 mutants are shown in the balls and labeled. AAV, adeno-associated virus.
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recognition of vector derived neoantigens must continue to be 
monitored in future trials to determine whether there are dose 
thresholds or specific response stimuli that can be avoided. 
Notwithstanding, the relationship remains elusive between T cell 
recognition and a response against transduced cells. Manno et al. 
reported contemporaneous increases in PBMCs that recognized 
the AAV2 capsid with an increase in transaminase levels and 
reduction in circulating FIX concentrations.23 In a recent study 
of AAV1-α-antitrypsin (AAT) gene delivery to muscle,28,29 T cell 
recognition of AAV capsid epitopes was also observed. In con-
trast to the FIX trial, quantitative examination of blood AAT levels 
suggested that the PBMC T cell recognition of AAV capsid did 
not have an impact on gene expression as it was stable over an 
extended duration.28,29 A recent publication by the Walker group 
suggests that in some scenarios peripheral PBMCs may become 
apoptotic in muscle tissue and a functional immune response 
targeting an antigen may be muted or curtailed.30 The impact 
of immunological recognition is likely to be multifactorial. For 
example, Vandenberghe described the generation of high levels 
of T cells against capsid of serotypes capable of binding heparin 
or heparan sulfate proteoglycans.31 Although AAV2.5 contains 
heparin binding capabilities we observed weak or minimal T cell 
activation to the AAV2.5 capsid using ELISPOT, suggesting that 
besides vector serotype and tropism, the route of administration, 
capsid particle dose, choice of promoter, and underlying disease 
pathology are likely to be critical determinants of any immune 
effector response.
Future directions
Pre-existing humoral immunity will continue to be a critical fac-
tor to be considered in the selection of study populations and 
in the determination of enrollment criteria. The general popu-
lation is exposed predominantly to AAV2 in the first decades 
of life.32 Patients with pre-existing high-titer Nab should be 
avoided in future trial designs. Effort is needed to continue the 
 development of novel chimeric AAV vectors that evade the com-
mon pre-existing Nab.33,34 Diminished seroprevalence of pre-ex-
isting crossreactive neutralizing antibodies is a goal of novel capsid 
development. The preliminary evaluation of AAV2.5 in vivo and 
preliminary study of humoral responses showed reduced cross-
reactivity to AAV2.5 in animal and human sera. The pre-exist-
ing humoral immunity to AAV2.5, we observed is attributable 
to AAV2 crossreactivity, with lower titers of  anti-AAV2.5 Nab 
being observed compared with titers of  anti-AAV2. These results 
support the predictive utility of the assays and methods used to 
develop the AAV2.5 capsid. However, we did observe less of a dif-
ference in crossreactivity between AAV2 and AAV2.5 Nab titers 
in the current study than in the preclinical evaluations, which 
could be due to the small sample sizes of both studies. As was 
seen in our studies, this ability to develop a new  generation of 
more tissue-selective gene vectors must be tempered with our 
limited abilities to predict human immunological recognition/
responses with the available preclinical models. Recent find-
ings suggest that pre-existing anti-AAV8 neutralizing titers of 
1:10 or greater may result in altered biodistribution patterns in 
nonhuman primates.35 This observation is of limited relevance 
to the current study that involved direct i.m. administration. 
However, future trials involving delivery via the vasculature may 
be impacted by this finding.
Immunological recognition of both capsid and transgene-en-
coded epitopes should be carefully monitored in any ongoing or 
future clinical study that targets DMD, in particular, potentially 
neoantigens not previously presented to the immune system, as 
well as antigens generated by revertant myofibers (see ref. 12).
The route of administration is known to impact upon the host 
immune response,36,37 and future trials of isolated limb delivery 
(Fan et al., this issue) and eventual systemic delivery will need to 
continue to monitor for immune responses. Intravascular AAV 
delivery results in some level of gene transfer to the liver, thymus, 
and spleen, which has been associated with transgene product tol-
erance in preclinical studies.38 Our preliminary preclinical limb 
perfusion study in the DMD dog model using AAV2i8, AAV8, or 
AAV9 mediated long-term minidystrophin expression  (data not 
shown). Although the immunological mechanisms behind these 
observations are unclear, either immune tolerance or T-cell apopto-
sis or both could favor blood-vessel-mediated AAV vector delivery 
to the muscle, which has a more uniform vector and antigen dis-
tribution than local i.m. injection. Given that regional limb deliv-
ery and eventual body wide delivery of the AAV vectors require 
proportionally higher vector doses of up to 1015 vg per patient, this 
will be associated with unprecedented foreign antigen load. The 
success of future clinical development of AAV based gene transfer 
for DMD will continue to require careful evaluation of the relation 
between vector doses, cell-mediated immune recognition and T 
cell immune response at all levels of preclinical and clinical devel-
opment. To this end we have initiated the next generation AAV 
capsid for efficient muscle delivery via vascular route that detargets 
liver but efficiently transduces muscle and cardiac tissue.39,40
MAterIAls And MetHods
Plasmid and DNA mutagenesis. The starting plasmid for these experi-
ments was the packaging plasmid pXR2.41 All plasmid mutagenesis was 
performed using either the Quick Change Multi Site Mutagenesis or the 
Quick Change Site Directed Mutagenesis kits (both from Stratagene, Santa 
Clara, CA). When possible, mutagenesis of multiple amino acids was done 
concurrently. When concurrent mutagenesis was not possible because dis-
tance between nucleotides was not optimal, mutagenesis was performed 
sequentially within inclusion of previous nucleotide changes within the 
new primer to prevent reversion. Accuracy of the nucleotide changes was 
verified by DNA sequence analyses followed by DNA subcloning to elimi-
nate any unwanted artifacts generated by the mutagenesis.
Recombinant virus production (preclinical studies). All recombinant 
AAV viruses were generated using the standard triple transfection method 
using the XX6-80 adenoviral helper plasmid with a packaging plasmid 
(either AAV1, AAV2 or a modified packaging plasmids) and an inverted 
terminal repeat plasmid [containing either green fluorescent protein, 
luciferase, or hAAT].42
rAAV was purified using standard methodology and the physical 
titer of the different viral preparations was evaluated using dot blot 
hybridization.42 For direct comparison of in vivo transduction efficiency, 
the vectors being compared within one experiment were evaluated on the 
same dot blot.
In vitro vector characterization. Batch binding of rAAV to heparin agarose 
was performed as described previously.43 The ability of the virus encoding 
the firefly luciferase complementary DNA to transduce cultured cells was 
also evaluated. Briefly, 293, Cos1, or HeLa cells were infected with 1,000 
Molecular Therapy  vol. 20 no. 2 feb. 2012 453
© The American Society of Gene & Cell Therapy
Clinical Evaluation of Custom-designed AAV Capsid in DMD Patients
particles of rAAV/cell and Ad dl309 at a multiplicity of infection of 10. Cells 
lysates were then assessed via luminometry 24 hours post-transduction.
Animals. C57BL and BALB/c mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). Animals were maintained and treated in 
accordance with the Animal Care and Use Committee of UNC Chapel Hill. 
All care and procedures were in accordance with the Guide for the Care 
and Use of Laboratory Animals (DHHS Publication No. [NIH] 85-23), and 
all procedures received prior approval by the University of North Carolina 
Institutional Animal Care and Usage Committee.
In vivo bioluminescence imaging of luciferase. 1 × 1010 viral 
 genome-containing particles (vg) were injected into the gastrocnemius 
male BALB/c mice. A total of six limbs were injected for each vector type 
using 25 µl of virus. The mice were anesthetized by intraperitoneal admin-
istration of 2.5% averdin. A solution of the luciferase substrate luciferin 
(150 mg/kg; Invitrogen, Carlsbad, CA) was injected intraperitoneally. A 
grey scale reference image of animals was generated and mice were imaged 
for 5 minutes using a NightOwl cabinet with charge couple device camera 
(Berthold Technologies, Bad Wildbad, Germany). Total photon emission 
from selected and defined areas within the images of each mouse was quan-
tified with the WinLight32 software (Berthold Technologies). The photon 
signal was presented as a pseudocolor image representing light intensity 
(red most and blue least intense). This image was superimposed on the 
reference image for orientation.
Detection of neutralizing anti-AAV antibodies. For comparison of 
humoral immune response among AAV capsids in mice, 100 µl phosphate-
buffered solution containing 1 × 1010 particles of rAAV/GFP virus for each 
capsid type was intraperitoneally injected into 6–10-week-old mice at day 
0, and boosted at day 14. Blood sera were collected from mice via retro-
orbital plexus at indicated time points or from human via peripheral vein. 
Nab titer was assayed using methodology described by Moskalenko et al. 
with slight modifications.44 Briefly, 293 cells were seeded in a 48-well plate 
at a density of 105 cells/well in 200 µl DMEM containing 10% fetal bovine 
serum. The cells were cultured for 3–4 hours at 37 °C and allowed to adhere 
to the well. AAV-GFP (1 × 108 particles) was incubated with mice sera at 
serial dilution with phosphate-buffered solution for 2 hours at 4 °C in a 
total volume of 25 µl. The mixture was added to cells in a final volume of 
200 µl which contained 4 × 10 6 particles of adenovirus dl309 and incu-
bated 24 hours or 48 hours at 37 °C. GFP-expressing cells were counted 
under a fluorescent microscope. The neutralizing antibody titer was cal-
culated using the highest dilution where the percentage of GFP expressed 
cells were 50% less than control without sera.
Readministration. For readministration application of AAV vectors 
in  vivo, mice were immunized with AAV/AAT vectors by muscular injec-
tion, and then challenged with AAV/luciferase vectors 2 months later. The 
luciferase transgene expression was measured 6 weeks following last vector 
injection.
Human subjects (preclinical). The sera from adult volunteers were 
screened for neutralizing antibodies to AAV. Individuals were research-
ers at the University of North Carolina at Chapel Hill (Chapel Hill, NC). 
The study was approved by the institutional review board of the University 
of North Carolina at Chapel Hill.
Homologous model building for AAV2.5. The available atomic coordinates 
for AAV2 (ref. 11; PDB accession No.1LP3) and AAV1 (L. Govindasamy 
and M. Agbandje-McKenna, unpublished results) were used to generate a 
homologous model for the AAV2.5 variant to enable comparison with the 
parental viruses. The model was generated by submitting the VP3 sequence 
of AAV2.5 to the SWISS-MOLEL model building program with the coor-
dinates of structures of the AAV1 and AAV2 VP3 supplied as template.45 
The model of AAV2.5 VP3 was then superimposed onto the AAV1 and 
AAV2 structures using the SSM option of the COOT program for com-
parative analysis.46,47 To visualize the location of the mutated residues in the 
context of an assembled capsid in the predicted structure of AAV2.5 ico-
sahedral symmetry operators were applied to the VP3 model coordinates 
by matrix multiplication using the program O and the amino acids were 
highlighted in the context of the symmetry related VPs.48 Figures show-
ing ribbon drawings and surface representations were generated using the 
program PyMOL.
Regulatory approval process. The clinical protocol and Appendix M 
documents were reviewed by the Recombinant DNA Advisory Committee 
under the auspices of the Office of Biotechnology Activities at the NIH. 
The Nationwide Children’s Hospital institutional review board approved 
the study protocol. A Pre-IND discussion was held with FDA prior to 
initiation of the pivotal toxicology and biodistribution study, and upon 
conclusion of preclinical studies the IND was submitted to CBER/FDA 
(BB-IND 12936). The trial is registered with ClinicalTrials.gov (Reference 
no. NCT00428935).
Study design. The experimental design was a randomized double-blind 
placebo-controlled study where vector was administered into one bicep 
and saline control in the contralateral arm. In a subset of patients, we sub-
stituted AAV empty capsid for saline in an effort to distinguish immune 
response to vector versus minidystrophin transgene. The active phase of 
the study included a 2-week baseline screening period, a 2-day inpatient 
period for vector injection and acute toxicity monitoring, and a 2-year out-
patient follow-up and toxicity-monitoring period. Ongoing long-term fol-
low-up will continue out to 15 years post vector injection (Supplementary 
Figure S1). Blood and urine analyses were conducted in conjunction with 
outpatient clinics on postadministration days 8, 15, 30, 43, 53, 60, 90, and 
120 and months 6, 9, 12, 18, and 24.
The trial was comprised by two-dose cohorts, with each patient 
receiving bilateral injections, with double-blinded randomization 
of AAV2.5-minidystrophin vector to one bicep and placebo to the 
contralateral bicep. Four patients received a saline placebo injection 
into the contralateral bicep, and two patients in dose cohort II received 
an empty capsids placebo injection into the contralateral bicep with an 
identical dose as of the minidystrophin-containing full capsids.
qPCR analysis of AAV2.5 vector genomes. DNA was isolated from frozen 
muscle biopsies using a Qiagen DNeasy Tissue kit. 0.5% of the recovered 
DNA from each sample was used as template in duplicate qPCR using 
three primer sets targeting the minidystrophin transgene and two primers 
targeting human genomic DNA reference sites at the laminB2 and globin 
loci (Supplementary Table S3). The minidystrophin primers crossed exon 
splicing junctions, so they specifically amplify the complementary DNA 
transgene but not the endogenous dystrophin gene. qPCR was performed.
Minidystrophin vector. The vector genome packaged in AAV2.5 encoded 
the aminoterminal actin-binding domain, five rod repeat domains (R1, 
R2, R22, R23, and R24), three hinge domains (H1, H3, and H4), and the 
cysteine-rich domain of the human dystrophin gene. The CMV immediate 
early promoter regulated transgene expression, along with a bovine growth 
hormone derived polyadenylation signal.
Both the test vector and the empty capsid reagents were generated by 
transient transfection of mammalian HEK293 cell cultures, undertaken at 
the Human Applications Laboratory, University of North Carolina.
With Dot–Blot tittering, the total lot yield was calculated as 1.72 × 1013 
vector genomes at a concentration of 4.4 × 1012 vector genomes/ml. This 
final product was then further diluted in sterile 1× phosphate-buffered 
solution 5% sorbitol to generate the clinical dose concentrations (see 
Table 2) for additional characterization and lot release testing. The 
clinical dose is determined by the vector genome dose, which is 6 × 1011 
vector genomes/subject in the first low dose cohort and 3 × 1012 vector 
genomes/subject in the second high dose cohort.
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Apart from two critical differences, the manufacturing procedures 
used in the production of the empty capsid lot were identical to those 
used in the production of rAAV2.5 minidystrophin. The first difference 
is merely the absence of the AAV-minidystrophin-containing plasmid 
in the cell transfection stage. The second difference is the use of a dot 
blot western to titer the empty capsids (in units of capsid particles) in the 
absence of a single-stranded DNA insert. The AAV2.5 CMV-empty capsid 
lot underwent nearly identical release testing (titering assays differed) to 
that performed for AAV2.5 CMV-3978, and in addition was released with 
a CoA using the same procedures.
Estimation of capsid particle titer. Transmission electron microscopy 
was undertaken to evaluate the ratio of genome-containing particles to 
the total number of genome-containing (full) or empty capsid particles, 
with the ratio estimated as being 0.907. The total dose of AAV2.5 capsid 
particles was then estimated from this ratio and the genomic particle titer 
generated by the dot blot assay.
Evaluation of T-cell reactivity to capsid derived peptides. Peripheral 
blood T cell responses to the novel AAV capsid were quantified by IFN-γ 
ELISpot assay, as described before.12 Briefly PBMC isolated on Ficoll 
hypaque gradients were cultured with synthetic peptides (20 amino acids 
in length, overlapping by 10 residues) that spanned the VP1 capsid protein. 
To identify individual peptides within a pool that elicited IFN-γ activity, 
so that each peptide was present in two of the intersecting mapping sub-
pools. After incubation at 37 °C for 36 hours. IFN-γ SFC were counted. 
Fewer than 10 SFC/well were observed with peptides from a control pool 
(enhanced GFP). Responses were considered positive when SFC exceeded 
50/106 PBMC in duplicate wells.
suPPleMentArY MAterIAl
Figure S1. Trial procedures timeline.
Figure S2. Temporal profiles of blood chemistry, hematology, and 
urinalyses.
Table S1. Genome detection in subject biopsies.
Table S2. Comparison of AAV.Minidys dose–response-related expression.
Table S3. Quantitative PCR primers.
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